Home | Sitemap | Search | ContactA- A A+
   
 
    Public Member Support us  
 

IBCSG 11-93 

Ovarian ablation followed by tamoxifen with or without 4 cycles of AC as adjuvant therapy for premenopausal women, node positive, hormone receptor positive breast cancer patients who are suitable for endocrine therapy alone.

DESIGN

Design Trial 11-93

Results & Publications


Publications

Study Chairs
Prof. Beat Thürlimann - St. Gallen, Switzerland
Prof. Monica Castiglione - Bern, Switzerland

Statistician
Karen Price

Lead Trial Coordinator
Holly Shaw

Director of Data Management
Lynette Blacher

IBCSG Data Management Center/FSTRF
4033 Maple Road
Amherst, New York 14226 USA
Phone: +1 716 834 0900
Fax: +1 716 833 3990
Email: ibcsg10-15@fstrf.org

Date of Activation
May 1, 1993

Date of Closure
November 1, 1998

Targeted Accrual
400 patients

Final Accrual
174 patients


Results Publications Results & Publications
Other Pathology


News

14.06.2020:
Save the date and join the IBCSG Pink Ladies! June 14, 2020

20.03.2020:
The next IBCSG Annual Meeting will take place in Barcelona Spain on March 20 and 21, 2020.       

11.11.2019:
New publications are available 

All News

 
  Print